MX9707732A - Compuestos triciclicos utiles en el tratamiento de desordenes proliferativos de celulas. - Google Patents

Compuestos triciclicos utiles en el tratamiento de desordenes proliferativos de celulas.

Info

Publication number
MX9707732A
MX9707732A MX9707732A MX9707732A MX9707732A MX 9707732 A MX9707732 A MX 9707732A MX 9707732 A MX9707732 A MX 9707732A MX 9707732 A MX9707732 A MX 9707732A MX 9707732 A MX9707732 A MX 9707732A
Authority
MX
Mexico
Prior art keywords
treatment
compounds useful
cell proliferative
proliferative disorders
tricyclic compounds
Prior art date
Application number
MX9707732A
Other languages
English (en)
Inventor
Ronald J Doll
Alan K Mallams
Adriano Afonso
Dinanath F Rane
F George Njoroge
Randall R Rossman
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX9707732A publication Critical patent/MX9707732A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos novedosos de la formula (1.0). También de describe un método para inhibir la funcion Ras y por lo tanto inhibir el crecimiento anormal de células. El método comprende administrar un compuesto de la formula a un sistema biologico. En particular, el método inhibe el crecimiento anormal de células en un mamífero tal como si fuera un humano.
MX9707732A 1995-04-07 1996-04-03 Compuestos triciclicos utiles en el tratamiento de desordenes proliferativos de celulas. MX9707732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41898295A 1995-04-07 1995-04-07
PCT/US1996/004168 WO1996031111A1 (en) 1995-04-07 1996-04-03 Tricyclic compounds useful in the treatment of cell proliferative disorders

Publications (1)

Publication Number Publication Date
MX9707732A true MX9707732A (es) 1997-12-31

Family

ID=23660318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9707732A MX9707732A (es) 1995-04-07 1996-04-03 Compuestos triciclicos utiles en el tratamiento de desordenes proliferativos de celulas.

Country Status (11)

Country Link
US (1) US5891872A (es)
EP (1) EP0819128B1 (es)
JP (1) JPH11503157A (es)
AT (1) ATE220400T1 (es)
AU (1) AU5432596A (es)
CA (1) CA2217680A1 (es)
DE (1) DE69622265T2 (es)
ES (1) ES2175087T3 (es)
IL (1) IL117782A0 (es)
MX (1) MX9707732A (es)
WO (1) WO1996031111A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002519427A (ja) 1998-07-02 2002-07-02 メルク エンド カムパニー インコーポレーテッド プレニル蛋白トランスフェラーゼ阻害薬
AU760027B2 (en) 1998-07-02 2003-05-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2001227757A1 (en) 2000-01-12 2001-07-24 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
WO2001051126A1 (en) 2000-01-12 2001-07-19 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2001227756A1 (en) 2000-01-12 2001-07-24 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
WO2001077114A1 (en) 2000-04-10 2001-10-18 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2005017160A2 (en) 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
PE20070427A1 (es) 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
PL2010528T3 (pl) 2006-04-19 2018-03-30 Novartis Ag 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
US7943622B2 (en) * 2006-06-06 2011-05-17 Cornerstone Therapeutics, Inc. Piperazines, pharmaceutical compositions and methods of use thereof
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
ES2452349T3 (es) 2007-05-21 2014-04-01 Novartis Ag Inhibidores de CSF-1R, composiciones, y métodos de uso
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2010144909A1 (en) 2009-06-12 2010-12-16 Novartis Ag Fused heterocyclic compounds and their uses
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CN103080093A (zh) 2010-03-16 2013-05-01 达纳－法伯癌症研究所公司 吲唑化合物及其应用
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2723717A2 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
AU2012272898A1 (en) 2011-06-24 2013-04-11 Amgen Inc. TRPM8 antagonists and their use in treatments
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017074914A1 (en) * 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
MX2019012233A (es) 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anticuerpos anti-sirpa.
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
KR102865307B1 (ko) * 2018-02-23 2025-09-26 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 수용체 억제제, 이를 포함하는 약학적 조성물 및 그 용도
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
WO2024180169A1 (en) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355036A (en) * 1980-06-19 1982-10-19 Schering Corporation Tricyclic-substituted piperidine antihistamines
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
US4826853A (en) * 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5104876A (en) * 1988-04-28 1992-04-14 Schering Corporation Benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use
NZ228889A (en) * 1988-04-28 1991-09-25 Schering Corp Fused tri- or tetracyclic heterocyclic compounds and pharmaceutical compositions
US4863931A (en) * 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US6083917A (en) * 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
IE68935B1 (en) * 1990-06-22 1996-07-24 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene piperidylidene and piperazine compounds compositions and methods of use
US5416091A (en) * 1990-12-18 1995-05-16 Burroughs Wellcome Co. Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JPH0676403B2 (ja) * 1991-01-18 1994-09-28 エスエス製薬株式会社 新規なベンゾ［５，６ シクロヘプタ［１，２−ｂ ピリジン誘導体及びこれを含有する抗アレルギー剤
JPH04356466A (ja) * 1991-01-28 1992-12-10 Mitsui Toatsu Chem Inc 新規キノリン誘導体及びそれを有効成分として含有する制癌剤効果増強剤
US5340828A (en) * 1991-09-30 1994-08-23 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
CA2165176A1 (en) * 1993-06-18 1995-01-05 Samuel L. Graham Inhibitors of farnesyl-protein transferase

Also Published As

Publication number Publication date
JPH11503157A (ja) 1999-03-23
EP0819128A1 (en) 1998-01-21
ATE220400T1 (de) 2002-07-15
WO1996031111A1 (en) 1996-10-10
EP0819128B1 (en) 2002-07-10
CA2217680A1 (en) 1996-10-10
IL117782A0 (en) 1996-08-04
ES2175087T3 (es) 2002-11-16
AU5432596A (en) 1996-10-23
US5891872A (en) 1999-04-06
DE69622265T2 (de) 2003-03-20
DE69622265D1 (de) 2002-08-14

Similar Documents

Publication Publication Date Title
MX9707732A (es) Compuestos triciclicos utiles en el tratamiento de desordenes proliferativos de celulas.
MX9707665A (es) Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas.
IL117799A0 (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
MX9707197A (es) Compuestos triciclicos de urea que son utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proliferativas.
TW334432B (en) Tricyclic amide and urea compounds
CA2216163A1 (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL111257A0 (en) Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
MX9804956A (es) Amidas triciclicas utiles para la inhibicion de la funcion de la proteina -g y para el tratamiento de las enfermedades proliferativas.
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
MY143570A (en) Compounds useful for inhibition of farnesyl protein transferase
AU2634597A (en) Compounds with growth hormone releasing properties
DE69926078D1 (en) Farnesyl-protein transferase inhibitoren
CA2293358A1 (en) Tricyclic sulfonamide inhibitors of farnesyl-protein transferase
ZA976754B (en) Novel tricyclic N-cyanoimines useful as inhibitors of farnesyl-protein transferase.
CA2293713A1 (en) Bispyrido-cycloheptane compounds useful for inhibition of farnesyl protein transferase
CA2293549A1 (en) Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
CA2293553A1 (en) Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees